RESUMO
Background: Recurrent Aphthous Stomatitis [RAS] is one of the most common diseases of the oral cavity all over the world [5-66%]. RAS has a multifactorial etiology, while psychological factors such as stress and anger play a role in its manifestation. The serotonergic mechanisms particularly the serotonin-transporter gene [5-HTT] may affect the risk of psychological alterations and stress response. The aim of the present study was to evaluate the polymorphism of the promoter region of 5-HTT [5-HTTLPR] in the patients with RAS, compared to that in the control subjects
Methods: In this case-control study, 100 patients with RAS and 100 healthy subjects were enrolled. PCR was performed on DNA of the samples, using a pair of primers capable of distinguishing S/L alleles and replicating 5-HTTLPR
Results: No statistically significant difference existed between LL and LS genotype frequencies in the case and control groups. However, SS genotype frequency was significantly higher in the case group, as compared to the control group [p=0.001]
Conclusion: The conclusion of the present study demonstrated that S allele could approximately double the risk of RAS
RESUMO
Recurrent aphthous stomatitis [RAS] is a common disease with unknown etiology. There is no curative treatment. Purslane is considered as a rich source of antioxidants with anti-inflammatory effects. The purpose of this study is to evaluate the effect of Purslane in the treatment of RAS. A total of 50 patients were selected for this randomized triple-blind placebocontrolled clinical trial from School of Dentistry of Tehran University of Medical Sciences in 2011. All subjects were randomly divided into two groups. Groups A and B received placebo and Purslane, respectively, for three months. Pain intensity based on the visual analogue scale [VAS], the mean intervals of lesions occurrence, number of lesions and the mean duration of complete healing at baseline and at months 1, 2 and 3 were recorded. While no patient complained from increased severity of pain, decreased severity of pain for 4, 3, 2, and 1 grades were recorded in%16,%20, 20%, and 40%, respectively, which were much higher than 4%, 8%, 8%, and 28%, respectively, in the control group. A significant decrease in pain intensity in VAS scores were seen after treatment in group B [P<0.001]. The mean duration of complete healing showed significant differences [P<0.001] between groups A [-1.52 +/- 4.07 days] and group B [-6.56 +/- 4.50 days]. The mean intervals between lesions also showed significant differences [P<0.001] between group A [17.88 days] and group B [33.12 days]. No significant differences were found between group A and group B regarding to number of lesions. No serious side-effects occurred in either group. According to our study, Purslane is clinically effective in treatment of RAS and considering the lack of side-effects during the study period, this medicine may be a favorable alternative treatment for recurrent aphthous stomatitis.